- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07503873
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector Device Versus Syringe in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the PK and safety of ublituximab SC at different sites of administration and relative bioavailability of ublituximab SC administered with a prefilled pen versus syringe.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: TG Therapeutics Clinical Support Team
- Phone Number: 1-877-575-8489
- Email: clinicalsupport@tgtxinc.com
Study Locations
-
-
-
Bihać, Bosnia and Herzegovina, 77000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Mostar, Bosnia and Herzegovina, 88000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Sarajevo, Bosnia and Herzegovina, 71000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Tuzla, Bosnia and Herzegovina, 75000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Zenica, Bosnia and Herzegovina, 72000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Rustavi, Georgia, 3700
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 101
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 114
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 159
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 179
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 0160
- Recruiting
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Shtip, North Macedonia, 2000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Skopje, North Macedonia, 1000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Bydgoszcz, Poland, 85-796
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Katowice, Poland, 40-686
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Katowice, Poland, 40-568
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kielce, Poland, 25-726
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Krakow, Poland, 31-826
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Lodz, Poland, 90-324
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Olsztyn, Poland, 10-561
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Poznan, Poland, 61-853
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Warsaw, Poland, 04-141
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Zabrze, Poland, 41-800
- Recruiting
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kragujevac, Serbia, 34 000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Chernihiv, Ukraine, 14001
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Chernihiv, Ukraine, 14029
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk, Ukraine, 76018
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk, Ukraine, 76493
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk, Ukraine, 76008
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 2000
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 2091
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 3037
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 3110
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 4050
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ukraine, 4211
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Lviv, Ukraine, 79010
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Lviv, Ukraine, 79029
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Odesa, Ukraine, 65009
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Poltava, Ukraine, 36011
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Ternopil, Ukraine, 46014
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Uzhhorod, Ukraine, 88018
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Vinnytsia, Ukraine, 21001
- Recruiting
- TG Therapeutics Investigational Trial Site
-
Vinnytsia, Ukraine, 21009
- Recruiting
- TG Therapeutics Investigational Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of relapsing multiple sclerosis (RMS) (2017 Revised McDonald criteria).
- Expanded Disability Status Scale (EDSS) score less than or equal to (≤) 5.5 at screening.
- Neurologically stable for more than (>) 30 days prior to screening and Day 1.
- Female participants of childbearing potential must consent to use an effective method of contraception from consent and for 6 months after the last dose of ublituximab.
Exclusion Criteria:
- Primary-progressive multiple sclerosis (PPMS) or inactive secondary progressive multiple sclerosis (SPMS).
- Active chronic disease of the immune system other than MS or immunodeficiency syndrome.
- Participants with significantly impaired bone marrow function or significant leukopenia or thrombocytopenia.
- Participants who received any approved therapy to treat MS within 5 half-lives of the medication prior to screening.
- Treatment with any investigational agent within 5 half-lives of the investigational drug prior to screening.
- Females who are pregnant or nursing.
Note: Other protocol-specified Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part 1: Ublituximab SC
Participants will receive ublituximab SC, using a syringe at one of three different sites of administration. |
Administered as an SC injection by a syringe.
Other Names:
Administered as an SC injection by prefilled pen.
Other Names:
|
|
Experimental: Part 2: Ublituximab SC
Participants will be randomized to receive ublituximab SC using either the prefilled pen or a syringe. |
Administered as an SC injection by a syringe.
Other Names:
Administered as an SC injection by prefilled pen.
Other Names:
Ublituximab will be administered as an SC injection by prefilled pen. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab
Time Frame: Up to Week 12
|
Up to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1: Plasma Concentrations of Ublituximab
Time Frame: Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to Week 120
|
Up to Week 120
|
|
Part 2: Percentage of Participants Reporting Their Level of Satisfaction With the SC Method of Administration of Ublituximab, Assessed by Therapy Administration Satisfaction Questionnaire-Subcutaneous (TASQ-SC)
Time Frame: Up to Week 96
|
Up to Week 96
|
|
Part 2: Minimum Plasma Concentration at steady state (Cminss) of Ublituximab
Time Frame: pre-dose and at multiple timepoints post-dose up to Week 120
|
pre-dose and at multiple timepoints post-dose up to Week 120
|
|
Maximum Plasma Concentration at steady state (Cmaxss) of Ublituximab
Time Frame: pre-dose and at multiple timepoints post-dose up to Week 120
|
pre-dose and at multiple timepoints post-dose up to Week 120
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TG1101-RMS-SC201
- 2025-523757-33-00 (Other Identifier: EU CT Number)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.